Max Planck Innovation is responsible for technology transfer from the research institutes of the Max Planck Society, Germany's leading basic research organization.
We are partners of both science and industry:
- We advise and support scientists at Max Planck Institutes in evaluating their inventions and filing patents.
- We mediate the transfer of inventions from Max Planck Institutes to industry.
- We support scientists at Max Planck Institutes in founding companies.
We perform an important task: the transfer of basic research results into products, which contribute to the economic and social progress.
RhoGEF12 inhibition for the prevention and therapy of cardiac hypertrophy, -fibrosis, and -failure
Our technologies are as varied as the Max Planck Institutes themselves
all Technology offers
Anti-Cancer Program Originating from LDC Reaches Clinical Trials
First LDC-lead structure successfully progressed by Bayer Pharma AG into clinical study phase
Do you want to receive our newsletter and press releases?